Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.41 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | CLK2 | P49760 | 1/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | TOP2A | P11388 | 7/20 | 0.41 |
| ▸ | TOP2B | Q02880 | 7/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4301363 | 0.89 | ADRB2 (0.39) | KCNH2ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL13666573 | 0.86 | TOP2A (0.49) | KCNH2ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL4302231 | 0.85 | KCNH2 (0.47) | KCNH2ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL4293955 | 0.85 | KCNH2 (0.44) | KCNH2ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL4304018 | 0.84 | KCNH2 (0.49) | KCNH2ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL4297669 | 0.84 | KCNH2 (0.49) | KCNH2ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL4302229 | 0.84 | KCNH2 (0.49) | KCNH2ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL12279579 | 0.82 | TOP2A (0.41) | KCNH2ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL5001592 | 0.81 | TOP2A (0.44) | KCNH2ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL4992199 | 0.81 | TOP2A (0.44) | KCNH2ALDH1A1KDM4EHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270379-A1 | QUINOLONE DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-10-29 | — | — | US | claimed |
| WO-2009131973-A1 | QUINOLONE DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-29 | — | — | WO | claimed |
| US-20090270379-A1 | QUINOLONE DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-10-29 | — | — | US | disclosed |
| US-20090270379-A1 | QUINOLONE DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-10-29 | — | — | US | disclosed |
| US-20090270379-A1 | QUINOLONE DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-10-29 | — | — | US | disclosed |
| WO-2009131973-A1 | QUINOLONE DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270379-A1 | QUINOLONE DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | NQO2, QARS1, NQO1 | KCNH2 3433/4885ALDH1A1 2331/4885KDM4E 2817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.